Published in Cancer Res on November 01, 2008
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol (2009) 3.99
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene (2009) 2.26
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A (2013) 2.15
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun (2014) 2.00
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol (2010) 1.98
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol (2010) 1.93
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res (2013) 1.66
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol (2015) 1.62
BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res (2011) 1.61
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Challenging issues in pediatric oncology. Nat Rev Clin Oncol (2011) 1.56
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 1.48
PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol (2010) 1.47
A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol (2010) 1.46
Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol (2010) 1.43
Pediatric low-grade gliomas. J Child Neurol (2009) 1.41
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics (2009) 1.40
Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet (2011) 1.36
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene (2009) 1.31
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS One (2012) 1.30
Large duplications at reciprocal translocation breakpoints that might be the counterpart of large deletions and could arise from stalled replication bubbles. Genome Res (2011) 1.30
Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev (2012) 1.30
MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2011) 1.28
Mining the O-mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. Proc Natl Acad Sci U S A (2013) 1.27
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell (2012) 1.26
An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest (2011) 1.25
Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol (2012) 1.19
Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet (2013) 1.19
Exomic sequencing of four rare central nervous system tumor types. Oncotarget (2013) 1.17
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A (2012) 1.15
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol (2012) 1.14
RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. Genome Res (2011) 1.14
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn (2011) 1.11
Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol (2011) 1.09
Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets (2010) 1.07
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene (2010) 1.07
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05
To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol (2013) 1.04
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res (2012) 1.02
Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Front Oncol (2015) 1.02
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun (2014) 1.00
Biology, genetics and imaging of glial cell tumours. Br J Radiol (2011) 1.00
Modern brain tumor imaging. Brain Tumor Res Treat (2015) 0.97
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol (2010) 0.96
MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol (2010) 0.96
Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro Oncol (2013) 0.95
MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro Oncol (2012) 0.95
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer (2015) 0.94
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res (2013) 0.92
Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 0.91
Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol (2012) 0.90
Novel BRAF Alteration in a Sporadic Pilocytic Astrocytoma. Case Rep Med (2012) 0.89
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood (2016) 0.89
Fusion genes and their discovery using high throughput sequencing. Cancer Lett (2013) 0.88
Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol (2012) 0.87
Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol (2012) 0.87
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol (2017) 0.86
RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab (2013) 0.86
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. Cell Mol Neurobiol (2014) 0.86
Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta (2014) 0.86
Intratumoral patterns of clonal evolution in gliomas. Neurogenetics (2009) 0.86
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res (2015) 0.85
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. Acta Neuropathol Commun (2014) 0.85
Vaccination strategies for neuro-oncology. Neuro Oncol (2015) 0.85
Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset. Int J Clin Exp Pathol (2010) 0.85
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. J Transl Med (2014) 0.84
The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. Mod Pathol (2016) 0.84
Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome. J Neurooncol (2010) 0.84
Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. Chin J Cancer (2013) 0.84
Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med (2015) 0.84
Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res (2011) 0.84
New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res (2013) 0.84
The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol (2014) 0.84
Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol (2016) 0.83
Molecular neuropathology of gliomas. Int J Mol Sci (2009) 0.83
An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.83
Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects. Genesis (2013) 0.83
Activation of the Hedgehog pathway in pilocytic astrocytomas. Neuro Oncol (2010) 0.82
Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet (2014) 0.82
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Computational detection and location of transcription start sites in mammalian genomic DNA. Genome Res (2002) 7.89
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene (2007) 1.97
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84
Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature. Childs Nerv Syst (1997) 1.63
RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology (2005) 1.55
Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J Neuropathol Exp Neurol (2006) 1.54
B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J Biol Chem (2005) 1.54
Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics (2007) 1.52
Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J Invest Dermatol (2007) 1.48
B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene (2007) 1.38
Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet Cytogenet (1998) 1.27
Ras oncogene mutations in childhood brain tumors. Cancer Epidemiol Biomarkers Prev (1997) 1.12
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
The DNA sequence of the human X chromosome. Nature (2005) 6.97
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol (2009) 3.99
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol (2008) 3.34
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A (2010) 2.91
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 2.50
Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry (2012) 2.48
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res (2007) 2.25
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer (2012) 2.24
Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol (2003) 2.06
The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein 1. Exp Dermatol (2007) 1.98
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell (2009) 1.92
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol (2011) 1.90
An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J Neurosci Methods (2009) 1.82
A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69
A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res (2010) 1.68
Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst (2013) 1.65
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol (2010) 1.58
Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J Neuropathol Exp Neurol (2006) 1.54
Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol (2013) 1.53
Replication timing of human chromosome 6. Cell Cycle (2005) 1.52
Decreased androgen receptor expression may contribute to spermatogenesis failure in rats exposed to low concentration of bisphenol A. Toxicol Lett (2013) 1.52
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer (2005) 1.48
Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa. Acta Derm Venereol (2011) 1.46
High-molecular-weight aggregates in repackaged bevacizumab. Retina (2010) 1.45
Enhanced Thermostability of Arabidopsis Rubisco activase improves photosynthesis and growth rates under moderate heat stress. Plant Cell (2007) 1.44
High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol (2006) 1.43
Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol (2007) 1.42
Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene (2006) 1.40
Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics (2006) 1.39
Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res (2011) 1.35
Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest (2006) 1.35
Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell Cycle (2006) 1.34
Complex chromosome 22 rearrangements in astrocytic tumors identified using microsatellite and chromosome 22 tile path array analysis. Genes Chromosomes Cancer (2005) 1.31
A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol (2011) 1.30
Expression of mineralization markers in dental pulp cells. J Endod (2007) 1.29
Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg Med Chem (2009) 1.28
Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2008) 1.25
Molecular pathogenesis of astrocytic tumours. J Neurooncol (2004) 1.24
Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur J Neurosci (2009) 1.22
Genome-wide identification of SOC1 and SVP targets during the floral transition in Arabidopsis. Plant J (2012) 1.20
Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther (2008) 1.20
Rescue of cystathionine beta-synthase (CBS) mutants with chemical chaperones: purification and characterization of eight CBS mutant enzymes. J Biol Chem (2010) 1.20
A review: recent advances and future prospects of taxol-producing endophytic fungi. Appl Microbiol Biotechnol (2010) 1.20
Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol (2005) 1.17
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol (2013) 1.15
Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol (2010) 1.14
Duodenal and nodal follicular lymphomas are distinct: the former lacks activation-induced cytidine deaminase and follicular dendritic cells despite ongoing somatic hypermutations. Mod Pathol (2009) 1.14
Tarsal and metatarsal bone mineral density measurement using volumetric quantitative computed tomography. J Digit Imaging (2008) 1.14
Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med (Berl) (2005) 1.14
The role of protein dynamics in thymidylate synthase catalysis: variants of conserved 2'-deoxyuridine 5'-monophosphate (dUMP)-binding Tyr-261. Biochemistry (2006) 1.14
A small family of sushi-class retrotransposon-derived genes in mammals and their relation to genomic imprinting. J Mol Evol (2005) 1.14
LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathol (2012) 1.12
The conformational dynamics of a metastable serpin studied by hydrogen exchange and mass spectrometry. Biochemistry (2006) 1.12
BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica (2011) 1.11
Multinodular and vacuolating neuronal tumor of the cerebrum. Brain Tumor Pathol (2014) 1.08
Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. Acta Neuropathol (2013) 1.08
Volumetric quantitative computed tomography measurement precision for volumes and densities of tarsal and metatarsal bones. J Clin Densitom (2011) 1.07
Fast classification and compositional analysis of cornstover fractions using Fourier transform near-infrared techniques. Bioresour Technol (2008) 1.03
AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol (2013) 1.03
Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res (2003) 1.02